Remepy Appoints Eran Harary, MD, to Propel Hybrid Drug Pipeline Forward

Remepy Welcomes New Chief Medical Officer

In an exciting development for the pharmaceutical industry, Remepy has announced the appointment of Dr. Eran Harary as their new Chief Medical Officer, effective October 1, 2026. Dr. Harary, a seasoned leader in pharmaceutical R&D, will play a pivotal role as the company gears up to advance its innovative Hybrid Drugs™ pipeline, especially focusing on treatments for Parkinson's disease.

Remepy, known for pioneering this new class of medication that merges traditional drugs with personalized, AI-driven therapeutic applications, aims to revolutionize patient care through its offerings. Dr. Harary joins the team from Teva Pharmaceuticals, where he held several high-profile positions, including Vice President and Global Head of Specialty R&D. His extensive experience in both early and late-stage drug development, particularly in neuroscience, perfectly aligns with Remepy's mission to shape the future of hybrid medicine.

New Beginnings in Drug Development

The integration of digital therapeutic interventions into conventional pharmacological treatments represents a significant shift in how drugs are conceptualized and delivered. As the healthcare landscape evolves, the potential to augment traditional pharmaceuticals with digital solutions opens new avenues for patient engagement and health outcomes. In his new role, Dr. Harary aims to leverage these advancements to propel Remepy's offerings forward.

"Bringing Dr. Harary on board at this pivotal stage ensures we have the leadership in place to not only develop our pipeline but also to navigate the complex regulatory environment that comes with it," stated Michal Tsur, PhD, and Or Shoval, Co-CEOs of Remepy. "His deep commitment to patient-centered innovation and extensive background in drug development make him the ideal leader for this next chapter in our journey."

Dr. Harary’s commitment to enhancing clinical development through patient-centric designs aligns seamlessly with Remepy’s values. He remarked, "We have invested significantly in optimizing medication, yet we’ve often overlooked the complementarity of non-pharmaceutical interventions. Today’s advancements in AI, digital technologies, and an evolving regulatory framework render the combination of traditional drugs with digital solutions not only possible but essential. I am excited to contribute to Remepy's vision and the forthcoming Phase III trials of Hybridopa.”

The Future of Hybrid Drugs

Hybrid Drugs represent a novel classification that integrates pharmacological treatments with adaptive interventions, shaping a new paradigm in healthcare. Remepy's lead program, Hybridopa, has already received positive feedback from Phase IIa clinical trials, and Dr. Harary's leadership is expected to amplify the momentum towards successful Phase III trials scheduled to commence in Q4 2026.

With the clinical landscape rapidly evolving, Remepy is well-positioned to capitalize on emerging trends in personalized medicine. Not only does this reflect a broader shift within the healthcare ecosystem towards integration and personalization, but it also signals a new era for drug development where patients can expect more effective, tailored treatment options.

As the sector adjusts to these advancements, the role of leaders like Dr. Harary will be crucial to navigate the complexities associated with blending traditional medicine with cutting-edge technology. Remepy is set to change the landscape for patients with Parkinson's disease and beyond. This innovative approach, supported by robust scientific findings, positions Remepy as a trailblazer in hybrid therapy delivery.

In conclusion, the appointment of Dr. Eran Harary as Chief Medical Officer heralds a new chapter not only for Remepy but for the entire pharmaceutical industry. With a focus on patient-centered innovation and a groundbreaking approach to combining drugs with therapeutic technologies, Remepy is poised to lead the charge into a new era of hybrid healthcare solutions.